阿托伐他汀钙对代谢综合征患者颈动脉内中膜厚度及其他相关指标的影响Δ

摘要

OBJECTIVE:To investigate the effect of atorvastatin calcium on the carotid intima-media thickness(IMT)and other related indicators in patients with metabolic syndrome(MS). METHODS:The data of 1 444 patients with MS were retrospectively analyzed and randomly divided into observation group(874 cases)and control group(570 cases)by different medication. All patients were given healthy lifestyle,antihypertensive,hypoglycemia and lowering blood lipid guidance. On this basis,treatment group was orally given atorvastatin calcium 20 mg,once every evening. The follow-up was conducted for 3 years. The clinic data in 2 groups was compared,including body mass index(BMI),waist circumference(WC),systolic blood pressure(SBP),diastolic blood pressure (DBP),pulse pressure(PP),IMT,total cholesterol(TC),triglyceride(TG),low conspired lipoprotein cholesterol(LDL-C),high density lipoprotein cholesterol(HDL-C),high-sensitivity C-reactive protein(hs-CRP),fasting plasma glucose(FPG)and incidence of adverse reactions before and after treatment. RESULTS:After treatment,compared with before and control group,the BMI、WC、SBP、DBP、PP、IMT、TC、TG、LDL-C、HDL-C、hs-CRP and FPG in observation group were significantly improved,only TG、LDL-C and HDL-C in control group were significantly improved,the differences were statistically significant(P<0.05). There were no obvious adverse reactions during treatment. CONCLUSIONS:Based on the conventional treatment,atorvastatin calcium can effectively improve the IMT and blood lipid,blood pressure and blood glucose of patients with MS,with good safety.%目的：探讨阿托伐他汀钙对代谢综合征（MS）患者颈动脉内中膜厚度（IMT）及其他相关指标的影响。方法：回顾性分析1444例MS患者资料。将所有患者资料按用药的不同分为观察组（874例）与对照组（570例）。对照组患者均给予健康生活方式、降压、降糖、调脂指导；观察组患者在对照组治疗的基础上给予阿托伐他汀钙片20 mg，口服，每晚1次。两组患者疗程均为3年。比较两组患者治疗前后体质量指数（BMI）、腰围（WC）、收缩压（SBP）、舒张压（DBP）、脉压差（PP）、颈动脉内中膜厚度（IMT）、总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）、高密度脂蛋白胆固醇（HDL-C）、超敏C反应蛋白（hs-CRP）、空腹血糖（FPG）及不良反应发生情况。结果：治疗后，观察组患者BMI、WC、SBP、DBP、PP、IMT、TC、TG、LDL-C、HDL-C、hs-CRP、FPG均较同组治疗前及对照组显著改善，对照组患者仅TG、LDL-C、HDL-C均较治疗前显著改善，差异均有统计学意义（P＜0.05）。两组患者用药期间均未见明显不良反应发生。结论：在常规治疗的基础上，阿托伐他汀钙可有效改善MS患者的IMT及其他血脂、血压、血糖指标，且安全性较好。